Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2022 16:30 ET | Source: Celsion Corporation

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct...
April 06, 2022 08:30 ET | Source: Celsion Corporation

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April...
April 06, 2022 08:30 ET | Source: Celsion Corporation

CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
April 01, 2022 08:00 ET | Source: Celsion Corporation

Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
March 31, 2022 08:30 ET | Source: Celsion Corporation

Celsion Corporation Reports 2021 Financial Results and Provides Business Update

Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE)...
March 24, 2022 09:00 ET | Source: Celsion Corporation

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
February 28, 2022 09:00 ET | Source: Celsion Corporation

Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...
February 28, 2022 08:30 ET | Source: Celsion Corporation

Celsion Corporation Announces Stock Consolidation

LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
February 17, 2022 08:30 ET | Source: Celsion Corporation

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...
January 31, 2022 08:00 ET | Source: Celsion Corporation

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 ...